Blinatumomab has demonstrated efficacy in B-cell acute lymphoblastic leukemia(B-ALL),achieving a measurable residual disease(MRD)negativity rate of 78%(1).Its addition to consolidation chemotherapy or administration p...Blinatumomab has demonstrated efficacy in B-cell acute lymphoblastic leukemia(B-ALL),achieving a measurable residual disease(MRD)negativity rate of 78%(1).Its addition to consolidation chemotherapy or administration prior to allogeneic hematopoietic stem cell transplantation(allo-HSCT)has been shown to significantly improve overall survival(OS)and relapse-free survival(RFS)in adult B-ALL patients(2,3).展开更多
To the Editor:Patients with relapsed or refractory(R/R)acute lymphoblastic leukemia(ALL)have a poor prognosis,with a 5-year overall survival(OS)ranging from 25%to 50%,and remission induction therapy is challenging.[1]...To the Editor:Patients with relapsed or refractory(R/R)acute lymphoblastic leukemia(ALL)have a poor prognosis,with a 5-year overall survival(OS)ranging from 25%to 50%,and remission induction therapy is challenging.[1]Allogeneic hematopoietic stem cell transplantation(HSCT)is the golden standard treatment for patients with R/R ALL.Before immunotherapy was introduced into clinical practice,a significant proportion of patients could not undergo HSCT because of serious adverse events from chemotherapy or the inability to achieve an acceptably deep remission.展开更多
基金supported by the National Natural Science Foundation of China(No.82170206 and No.82470213)Project of Disciplines of Excellence(No.20234Z0002)。
文摘Blinatumomab has demonstrated efficacy in B-cell acute lymphoblastic leukemia(B-ALL),achieving a measurable residual disease(MRD)negativity rate of 78%(1).Its addition to consolidation chemotherapy or administration prior to allogeneic hematopoietic stem cell transplantation(allo-HSCT)has been shown to significantly improve overall survival(OS)and relapse-free survival(RFS)in adult B-ALL patients(2,3).
基金supported by grants from the project(No.RDJP2022-71)Peking University People’s Hospital Scientific Research Development Funds and the CAMS Innovation Fund for Medical Sciences(CIFMS)(No.2019-I2M-5-034).
文摘To the Editor:Patients with relapsed or refractory(R/R)acute lymphoblastic leukemia(ALL)have a poor prognosis,with a 5-year overall survival(OS)ranging from 25%to 50%,and remission induction therapy is challenging.[1]Allogeneic hematopoietic stem cell transplantation(HSCT)is the golden standard treatment for patients with R/R ALL.Before immunotherapy was introduced into clinical practice,a significant proportion of patients could not undergo HSCT because of serious adverse events from chemotherapy or the inability to achieve an acceptably deep remission.
基金support from the UK National Institute of Health Research(NIHR)Biomedical Research Centre and the Ministry of Science and Technology of China (84000-51200002)funded by an internal grant of the Iuliu Hatieganu University-School of Doctoral Studies+4 种基金funded by an internal grant of the Iuliu Hatieganu University-School of Medicinesupported by agrant from the Romanian National Ministry of Research,Innovation and Digitalization(PN-Ⅲ-P4-ID-PCE-20201118within PNCDI Ⅳ,Projects for Exploratory MedicineProjects for Exploratory Medicine-PCE 225/202)a national grant awarded to Young Research Teams(PN-Ⅲ-PI-1.1-TE-20190271)an international collaborative grant of the European Economic Space between Romania and Iceland 2021-2023:(Cooperation strategy for knowledge transfer,internationalization and curricula innovation in the field of research education at the 3rd level of study-AURORA)
